Jazz Pharmaceuticals (JAZZ) Prices $850M Notes Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Goldman Sachs sees 18% upside for Palantir on sovereign AI growth
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Citi names 5 top chip picks ahead of Q3 earnings
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
September 4, 2024 12:00 AM EDTDUBLIN, Sept. 4, 2024 /PRNewswire/ --Â Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified... More



